141 related articles for article (PubMed ID: 20689759)
1. Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines.
McClaine RJ; Marshall AM; Wagh PK; Waltz SE
Neoplasia; 2010 Aug; 12(8):650-8. PubMed ID: 20689759
[TBL] [Abstract][Full Text] [Related]
2. Dependency of Tamoxifen Sensitive and Resistant ER
Bhasin S; Dusek C; Peacock JW; Cherkasov A; Wang Y; Gleave M; Ong CJ
Cells; 2023 Jun; 12(13):. PubMed ID: 37443749
[TBL] [Abstract][Full Text] [Related]
3. G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer.
Cheriyath V; Kuhns MA; Jacobs BS; Evangelista P; Elson P; Downs-Kelly E; Tubbs R; Borden EC
Oncogene; 2012 Apr; 31(17):2222-36. PubMed ID: 21996729
[TBL] [Abstract][Full Text] [Related]
4. The MSP-RON axis stimulates cancer cell growth in models of triple negative breast cancer.
Millar R; Kilbey A; Remak SJ; Severson TM; Dhayade S; Sandilands E; Foster K; Bryant DM; Blyth K; Coffelt SB
Mol Oncol; 2020 Aug; 14(8):1868-1880. PubMed ID: 32484599
[TBL] [Abstract][Full Text] [Related]
5. Alcohol Regulates Genes that Are Associated with Response to Endocrine Therapy and Attenuates the Actions of Tamoxifen in Breast Cancer Cells.
Candelaria NR; Weldon R; Muthusamy S; Nguyen-Vu T; Addanki S; Yoffou PH; Karaboga H; Blessing AM; Bollu LR; Miranda RC; Lin CY
PLoS One; 2015; 10(12):e0145061. PubMed ID: 26661278
[TBL] [Abstract][Full Text] [Related]
6. Mammalian enabled protein enhances tamoxifen sensitivity of the hormone receptor-positive breast cancer patients by suppressing the AKT signaling pathway.
He L; She C; Jiang S; Qi Z; Deng Z; Ji L; Cui Y; Wu J
Biol Direct; 2024 Mar; 19(1):21. PubMed ID: 38459605
[TBL] [Abstract][Full Text] [Related]
7. An Introduction and Overview of RON Receptor Tyrosine Kinase Signaling.
Hunt BG; Fox LH; Davis JC; Jones A; Lu Z; Waltz SE
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833444
[TBL] [Abstract][Full Text] [Related]
8. Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.
Stires H; Heckler MM; Fu X; Li Z; Grasso CS; Quist MJ; Lewis JA; Klimach U; Zwart A; Mahajan A; Győrffy B; Cavalli LR; Riggins RB
Mol Cell Endocrinol; 2018 Aug; 471():105-117. PubMed ID: 28935545
[TBL] [Abstract][Full Text] [Related]
9. A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.
Chakedis J; French R; Babicky M; Jaquish D; Howard H; Mose E; Lam R; Holman P; Miyamoto J; Walterscheid Z; Lowy AM
Oncogene; 2016 Jun; 35(25):3249-59. PubMed ID: 26477314
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors.
Kim H; Whitman AA; Wisniewska K; Kakati RT; Garcia-Recio S; Calhoun BC; Franco HL; Perou CM; Spanheimer PM
Clin Cancer Res; 2023 Dec; 29(23):4894-4907. PubMed ID: 37747807
[TBL] [Abstract][Full Text] [Related]
11. Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.
De Marchi T; Timmermans AM; Smid M; Look MP; Stingl C; Opdam M; Linn SC; Sweep FC; Span PN; Kliffen M; van Deurzen CH; Luider TM; Foekens JA; Martens JW; Umar A
Oncotarget; 2016 Jan; 7(3):3098-110. PubMed ID: 26657294
[TBL] [Abstract][Full Text] [Related]
12. Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer.
Jiang C; Zhu Y; Chen H; Lin J; Xie R; Li W; Xue J; Chen L; Chen X; Xu S
Cell Death Dis; 2023 Oct; 14(10):653. PubMed ID: 37803002
[TBL] [Abstract][Full Text] [Related]
13. Tumor cell intrinsic RON signaling suppresses innate immune responses in breast cancer through inhibition of IRAK4 signaling.
Bourn JR; Ruiz-Torres SJ; Hunt BG; Benight NM; Waltz SE
Cancer Lett; 2021 Apr; 503():75-90. PubMed ID: 33508385
[TBL] [Abstract][Full Text] [Related]
14. RON (
Hunt BG; Jones A; Lester C; Davis JC; Benight NM; Waltz SE
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626096
[TBL] [Abstract][Full Text] [Related]
15. Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression.
Beauvais DM; Nelson SE; Adams KM; Stueven NA; Jung O; Rapraeger AC
J Biol Chem; 2022 Jun; 298(6):102029. PubMed ID: 35569509
[TBL] [Abstract][Full Text] [Related]
16. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.
Wang MH; Padhye SS; Guin S; Ma Q; Zhou YQ
Acta Pharmacol Sin; 2010 Sep; 31(9):1181-8. PubMed ID: 20694025
[TBL] [Abstract][Full Text] [Related]
17. The novel role of miRNAs for tamoxifen resistance in human breast cancer.
Zhang W; Xu J; Shi Y; Sun Q; Zhang Q; Guan X
Cell Mol Life Sci; 2015 Jul; 72(13):2575-84. PubMed ID: 25782411
[TBL] [Abstract][Full Text] [Related]
18. MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy.
Yao HP; Tong XM; Hudson R; Wang MH
J Exp Clin Cancer Res; 2020 Sep; 39(1):198. PubMed ID: 32962738
[TBL] [Abstract][Full Text] [Related]
19. RON-augmented cholesterol biosynthesis in breast cancer metastatic progression and recurrence.
Hunt BG; Davis JC; Fox LH; Vicente-Muñoz S; Lester C; Wells SI; Waltz SE
Oncogene; 2023 May; 42(21):1716-1727. PubMed ID: 37029299
[TBL] [Abstract][Full Text] [Related]
20. Ron receptor tyrosine kinase signaling as a therapeutic target.
Benight NM; Waltz SE
Expert Opin Ther Targets; 2012 Sep; 16(9):921-31. PubMed ID: 22834780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
